Advertisement

Cardiovascular Outcomes with Two “Gliptin” Drugs

September 2, 2013

Cardiovascular Outcomes with Two “Gliptin” Drugs

  1. Allan S. Brett, MD

In fairly short studies, saxagliptin and alogliptin neither decreased nor increased the incidence of major adverse CV events.

  1. Allan S. Brett, MD

In two industry-sponsored, randomized, international trials, investigators examined the effect of dipeptidyl peptidase–4 (DPP-4) inhibitors on the primary endpoint of cardiovascular-related death, myocardial infarction, or stroke in patients with type 2 diabetes. The studies were conducted in response to the FDA's requirement that cardiovascular safety be demonstrated for new diabetes drugs.

In one trial, 16,500 patients (mean age, 65; median duration of diabetes, 10 years) with additional cardiovascular risk factors or known cardiovascular disease received saxagliptin (Onglyza) or placebo. During average follow-up of 2 years, the primary endpoint occurred with near-identical frequency in the two groups (7.3% and 7.2%). No differences in secondary cardiovascular endpoints were noted, except for slightly higher incidence of heart failure hospitalizations with saxagliptin (3.5% vs. 2.8%; P=0.007). Mean glycosylated hemoglobin (HbA1c) was 0.2% lower in the saxagliptin group than in the placebo group, and hypoglycemia was more common with saxagliptin (15.3% vs. 13.4%; P<0.001).

In the other trial, 5400 diabetic patients who had suffered acute coronary syndrome during the previous 3 months received either alogliptin (Nesina) or placebo. During median follow-up of 1.5 years, the incidence of the primary endpoint was 11.3% with alogliptin and 11.8% with placebo, indicating noninferiority (but not superiority) of alogliptin. Alogliptin lowered HbA1c by 0.3% compared with placebo but did not increase risk for hypoglycemia.

Comment

Some people will emphasize that these “gliptin” drugs seem relatively safe, with no major adverse cardiovascular effects (although the unexpected slight excess of heart failure cases with saxagliptin should be noted). Others will emphasize that the drugs failed to improve cardiovascular outcomes. Either way, the appropriate role for these drugs remains unclear, given their very high cost (about US$4000 annually) and uncertainty about their long-term effects on clinically meaningful outcomes.

  • Disclosures for Allan S. Brett, MD at time of publication Nothing to disclose

Citation(s):

Reader Comments (1)

Julka Physician, Endocrinology, Synergy

For developing nations where. cost of therapy is borne by the patient and is a determinant of compliance this my be good news in disguise as we physicians won't be obliged to write the expensive drugs. For some they may be appropriate but for the majority of our patients who do well on meformi n a d a suck ylurea

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement